The incidence appears to be increasing.
We reviewed medical records of patients without known HIV and with positive cultures for nontuberculous mycobacteria (NTM) isolated during 2000–2003 from 1 large hospital in New York, New York. Overall, 505 patients had positive NTM cultures; 119 (24%) met the criteria for NTM disease. The difference between demographic characteristics of case-patients in our study (66% female, 61% white, and 59% >60 years of age) and those of the base population as determined by regional census data was statistically significant. Estimated incidences for positive cultures, all disease, and respiratory tract disease were 17.7, 2.7, and 2.0 per 100,000 persons, respectively. More patients with rapidly growing mycobacteria (61%),
Although the pathogenic potential of nontuberculous mycobacteria (NTM) was reported throughout the 20th century, widespread appreciation of the clinical syndromes caused by NTM began during the 1980s in association with the AIDS pandemic and the consequent dramatic increase in disseminated
To expand our understanding of the epidemiology of NTM, we reviewed the demographic and clinical characteristics of patients without known HIV infection who had positive cultures for NTM from 2000–2003. We sought to determine the incidence of NTM disease and colonization, the risk factors for NTM disease, and the species of mycobacteria associated with different clinical syndromes at our urban medical center.
We conducted a retrospective study of patients without known HIV infection and with positive cultures for NTM obtained during 2000–2003 at Columbia University Medical Center (CUMC), New York-Presbyterian Hospital, the only medical center in northern Manhattan. The study was approved by the Institutional Review Board of Columbia University.
Study patients had positive cultures for NTM and no laboratory evidence of HIV infection. Our mycobacteriology laboratory compiled the medical record numbers of patients with positive NTM cultures from 2000 through 2003. To maintain privacy regarding HIV status, the list was electronically purged of the names of patients with positive HIV serologic test results, patients with HIV viral load, and patients who had had genotyping studies performed. Patients identified in clinical notes as HIV infected were excluded.
Demographic characteristics, coexisting medical illnesses, and results of computed tomography (CT) studies of the chest and mycobacteriologic studies were collected from electronic medical records. These records were generally complete for demographic characteristics and clinical microbiology laboratory, surgical, and radiographic reports but sometimes lacked progress notes or treatment records, which were often written by hand in bedside charts. Electronic medical records were considered adequate to assess risk factors if the clinical notes (progress notes, consultation notes, discharge summaries) documented the medical history, coexisting illnesses, and medication regimens, including use of antimycobacterial agents.
Patients with blood cultures or tissue biopsy specimens positive for NTM were considered to have NTM disease. Patients with positive respiratory tract cultures were considered to have pulmonary disease if they met the following American Thoracic Society (ATS) guidelines (
We estimated the annual incidence of NTM disease by using previously described methods (
The demographic characteristics of the study patients were compared with those of the New York Public Health Department (NYPH) catchment population using 2000 US Census data (
Associations and confidence intervals (CIs) were calculated with SAS 9.1 (SAS Institute Inc., Cary, NC, USA) and EpiInfo 3.3.2 (Centers for Disease Control and Prevention, Atlanta, GA, USA). Single-proportion CIs were derived from the binomial distribution with continuity correction. We calculated CIs for the incidence estimate by using the formula provided by the National Center for Health Statistics (
During the 4-year study period, the clinical microbiology laboratory identified 769 patients with at least 1 positive NTM culture. Of these, 264 were excluded from further analysis by electronic purge of HIV-infected patients as previously described (
Flowchart of patient selection for cases of nontuberculous mycobacteria (NTM) colonization and NTM disease among patients without HIV infection, New York–Presbyterian Hospital (NYPH), Columbia University Medical Center, 2000–2003.
| NTM species* | No. positive cultures | Adequate data to assess case status† | No. patients with disease (%)‡ |
|---|---|---|---|
| All species | 505 | 375 | 119 (32) |
| 422 | 297 | 79 (27) | |
| Rapidly growing mycobacteria‡ | 45 | 41 | 25 (61) |
| | 14 | 13 | 11 (85) |
| | 15 | 13 | 4 (31) |
| | 16 | 15 | 10 (67) |
| 25 | 6 | 0 | |
| 12 | 10 | 7 (70) | |
| 4 | 4 | 4 (100) | |
| 5 | 4 | 0 | |
| 13 | 9 | 5 (56) |
*
Of the 505 study patients with NTM-positive cultures, 375 (74%) had adequate clinical data to determine disease status. In all, 119 (32%) of 375 were considered to have NTM disease (
Although only 24% (81/344) of patients with NTM-positive cultures from the respiratory tract met ATS criteria for NTM disease, 68% of cases of disease occurred in the respiratory tract (
| Site of disease | No. patients with MAC infection | No. patients with RGM infection | No. patients with other species infections | Total no. patients (%) |
|---|---|---|---|---|
| Respiratory tract | 65 | 7 | 9 | 81 (68.1) |
| Skin and soft tissue, nonsurgical | 2 | 4 | 6 | 12 (10.1) |
| Surgical sites | 0 | 7 | 2 | 9 (7.6) |
| Bloodstream | 2 | 4 | 1 | 7 (5.9) |
| Lymph node | 5 | 1 | 0 | 6 (5.0) |
| Disseminated | 2 | 0 | 0 | 2 (1.7) |
| Central nervous system | 0 | 1 | 0 | 1 (0.8) |
| Gastrointestinal tract | 0 | 0 | 1 | 1 (0.8) |
| All body sites | 76 | 24 | 19 | 119 (100) |
*MAC,
Skin and soft tissue sites were the second most common sites of disease and occurred in 21 (18%) patients. RGM caused 4 (33%) of 12 nonsurgical skin and soft tissue infections and 7 (78%) of 9 surgical wound infections. Seven of the latter were associated with cosmetic procedures; 4 had been performed in the Dominican Republic, 2 in Ecuador, and 1 in the United States. All 4 cases of
Seven patients had bloodstream infections (5 with RGM and 2 with MAC). Two additional subjects had positive blood cultures (both with MAC) and other infected body sites and, thus, were categorized with disseminated disease.
Of the 11 patients with MAC cultured from the GI tract, 7 had adequate clinical information to assess disease status. Two (29%) of 7 had disseminated disease as described above, and 5 had no clinical signs or symptoms of infection.
No patients had NTM disease of the urinary tract. One patient had 4 urine cultures positive for MAC but was not categorized as having NTM disease because no symptoms of urinary tract infection and no treatment with antimycobacterial agents had been documented.
Data from the 2000 US Census showed that 276,032 people resided within 5 ZIP codes that are closer to our medical center than any other hospital. During the study period, 37% of the 536,875 patients cared for at CUMC listed their home addresses within these 5 ZIP codes. Adjusted for the HIV prevalence rate of ≈1.5% in New York City, the base HIV-negative population was 271,892. Overall, 192 (38%) of 505 patients with positive cultures for NTM and 29 (24%) of 119 patients with NTM disease resided in this same area. Thus, the estimated annual incidences of patients with positive NTM cultures in the area defined by these 5 ZIP codes, NTM disease (inclusive of the respiratory tract), and NTM disease specifically of the respiratory tract were 17.7 (95% CI 15.2–20.2), 2.7 (95% CI 1.8–3.8), and 2.0 (95% CI 1.3–3.1) cases per 100,000 persons, respectively.
By adjusting 2000 US Census data for age, the expected proportion of women in the base population was 57% (
Distribution by sex of patients with positive nontuberculous mycobacteria (NTM) cultures, NTM disease, and disease of the respiratory tract caused by
The overall distribution of race and ethnicity was significantly different for patients with positive NTM cultures (p<0.01) or disease (p<0.001) when compared with the age-adjusted base population (
Distribution by race of patients with positive nontuberculous mycobacteria (NTM) cultures, NTM disease, and disease of the respiratory tract caused by
The median age of the study patients with positive NTM cultures was 66 years. Most (59%, n = 70) patients with disease were >60 years of age; only 8% (n = 9) were children <15 years of age. Patients with MAC disease were older than those with RGM disease (68 vs. 53 years of age, respectively, p<0.01). The median ages of patients with disease of the respiratory tract caused by different species were similar (71 years vs. 69 years of age for MAC and RGM, respectively); patients with nonpulmonary disease caused by MAC were substantially younger than those with nonpulmonary disease caused by RGM (11 vs. 41 years of age, respectively).
The ZIP codes of patients with positive NTM cultures were compared with those of all patients registered at CUMC. Patients with positive cultures were less likely to live in northern Manhattan within 3 miles of the medical center than were the hospital’s overall patient population (OR 0.72, p<0.001). In contrast, substantially more patients with positive cultures resided in the northwestern area of the Bronx (OR 2.17, p<0.001) or in Staten Island (OR 2.25, p<0.001).
At least 1 coexisting illness or concomitant medication considered to be a potential risk factor for NTM disease was noted for 73% of patients who fulfilled the study case definitions for disease. Ninety-four (79%) of 119 patients with NTM disease had adequate data to assess their medical histories, and 66% (62/94) had
| Site of NTM disease | % Patients with coexisting condition (n = 94) | ||||
|---|---|---|---|---|---|
| Lung disease | Transplant recipient | Immunocompromised* | Cancer | None | |
| Blood (n = 7) | 0 | 0 | 33 | 67 | 0 |
| Respiratory tract (n = 81) | 63 | 9 | 16 | 13 | 28 |
| Skin and soft tissue, surgical sites (n = 21) | 6 | 19 | 25 | 6 | 62 |
| All† | 44 | 11 | 18 | 17 | 34 |
| Site of NTM disease | % Patients receiving concomitant medications (n = 79) | ||||
|---|---|---|---|---|---|
| Systemic steroids | Immunosuppressants | Chemotherapeutics | Immunomodulators | None | |
| Blood (n = 7) | 50 | 33 | 50 | 17 | 17 |
| Respiratory tract (n = 81) | 26 | 13 | 2 | 4 | 70 |
| Skin and soft tissue, surgical sites (n = 21) | 17 | 17 | 8 | 8 | 75 |
| All† | 25 | 15 | 6 | 5 | 66 |
*Defined as diabetes, chronic renal failure and/or rheumatologic disease. †Includes 2 patients with disseminated disease following bone marrow transplantation, 1 patient with central nervous system disease receiving steroids, 1 patient with gastrointestinal disease, and 2 patients with lymph node disease/cancer.
Eighteen percent of patients had
For 79 (66%) of 119 patients with NTM disease, data were adequate to assess concomitant medications. Steroids or other immunosuppressive medications were prescribed for 25% and 15% of patients, respectively, within the 6 months before the first positive NTM culture. Although the use of steroids did not predict the site of NTM disease, the use of other immunosuppressive medications was less common in those with disease of the respiratory tract compared with those with disease of nonrespiratory sites (OR 0.30, 95% CI 0.10–0.89, p<0.05). However, when body site was adjusted for, patients with MAC were more likely to have received steroids than were those infected with other species (OR 5.2, 95% CI 1.2–24, p = 0.03). Also, more patients with bloodstream infections received cancer chemotherapeutics than did patients with disease of other body sites (OR 28, 95% CI 3.6–220, p<0.01).
This study is one of the largest recent studies of NTM and reflects the current epidemiology and risk factors for disease and colonization with these microorganisms as assessed in our medical center in northern Manhattan. The rate of NTM disease observed in patients without HIV infection appears to be increasing, but it is difficult to compare studies because different epidemiologic methodols have been used. In a laboratory survey from 1993 to 1996 performed by the Centers for Disease Control and Prevention, the rate of positive NTM cultures was 7.5–8.2 cases per 100,000 persons, compared with our positive culture rate of 17.7 per 100,000 (
Variation in the rates of NTM disease and colonization among different populations may also reflect differences in the risk for exposure to environmental mycobacteria. Our data demonstrate geographic variations in the incidence of NTM disease within New York City. Although neighborhood demographics may act as confounding variables, these findings suggest that environmental factors deserve further study. For example, patients residing in the northwestern Bronx had higher rates of disease with NTM; this area receives water from the smaller Croton Reservoir as opposed to the Catskills-Delaware Reservoir that supplies most of New York City (
Our study provided an opportunity to study risk factors in a population without referral center bias that can occur in centers specializing in NTM care. The predominance of women among persons with NTM disease is consistent with previous reports (
Only one-third of patients with positive cultures for NTM were categorized with disease. A significantly higher proportion of patients with positive cultures for RGM,
Among the expected risk factors for NTM disease, we found that preexisting pulmonary conditions were most common. However, many cases of NTM disease occurred in patients with concurrent illnesses or medications that were immunosuppressive. Our finding that MAC was the most common pathogen causing posttransplant NTM disease was consistent with results of prior studies (
Our study did have limitations. We used a convenience sample of patients receiving care at our medical center, which introduced potential bias if our sample was not representative of the general population. Our findings may not be applicable to other geographic regions, particularly given the different rates of disease we noted among different areas in New York City. The rare nature of NTM disease makes an accurate measure of the incidence in the population exceptionally difficult. Our incidence rate calculation was a gross estimate and likely an underestimate. Patients residing in the selected base population may have sought care elsewhere; patients with positive cultures and presumptive colonization may have progressed to active disease; and our case-patients were often hospitalized at the time of diagnosis, which suggests limited detection of outpatient cases. In addition, the high proportion of hospitalized case-patients could overestimate coexisting illnesses and concomitant medications. Potential cases of respiratory tract disease could have been missed due to incomplete data, usually a lack of chest CT results. Cultures or radiographic imaging may have been performed at other medical facilities, which could have resulted in misclassification of disease status. Racial differences could reflect, in part, differential access to healthcare. Furthermore, although CUMC is not a referral center for NTM, it is a referral center for other conditions, including lung transplantation.
In conclusion, we found an increased incidence of NTM-positive cultures and disease compared with results in previous reports. Our results suggest that laboratory-based surveillance may produce reasonable estimates of the incidence of nonrespiratory tract disease and of disease caused by RGM,
We thank Alla Babina for technical support.
This study was part of a master’s thesis in epidemiology by Ethan Bodle at the Mailman School of Public Health, Columbia University, and was presented in part as a poster at the American Thoracic Society 101st International Conference, San Diego, California, May 2005.
Dr Bodle is an emergency medicine resident at St. Luke’s Roosevelt Hospital Center, a Columbia University–affiliated hospital in New York, New York. His research interests include public health and epidemiology.